The clinical effectiveness of a physiotherapy delivered physical and psychological group intervention for older adults with neurogenic claudication: the BOOST randomised controlled trial

Esther Williamson PhD^{1,11}, Graham Boniface MRes¹, Ioana R Marian MSc², Susan J Dutton MSc², Angela Garrett¹, Alana Morris MSc¹, Zara Hansen PhD¹, Lesley Ward PhD³, Philippa JA Nicolson PhD¹, David Rogers MSc⁴, Karen L Barker PhD^{1,5}, Jeremy Fairbank MD, FRCS¹, Judith Fitch⁶, David P French PhD⁷, Christine Comer PhD^{8,9}, Christian D Mallen PhD¹⁰ and Sarah E Lamb DPhil¹¹ on behalf of the BOOST Research Group.

¹Nuffield Department of Rheumatology, Orthopaedics and Musculoskeletal Sciences, University of Oxford, UK

²Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK

³Department of Sport, Exercise and Rehabilitation, Northumbria University, UK

⁴Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, UK

⁵Oxford University Hospitals NHS Trust, Oxford, UK

⁶Patient and Public Involvement Representative

⁷Manchester Centre for Health Psychology, University of Manchester, UK

⁸University of Leeds, Leeds, UK

⁹Leeds Community Healthcare NHS Trust, Otley, UK

¹⁰Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK

¹¹College of Medicine and Health, University of Exeter.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

[©] The Author(s) 2022. Published by Oxford University Press on behalf of The Gerontological Society of America.

Correspondence to: Dr Esther Williamson, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Building, Windmill Road, Oxford, OX3 7LD, UK. Tel: +44 1865 223120; Email: esther.williamson@ndorms.ox.ac.uk

Recei

Abstract:

Background: Neurogenic claudication (NC) is a debilitating spinal condition affecting older adults' mobility and quality of life.

Methods: A randomised controlled trial of 438 participants evaluated the effectiveness of a physical and psychological group intervention (BOOST programme) compared to physiotherapy assessment and tailored advice (best practice advice [BPA]) for older adults with NC. Participants were identified from spinal clinics (community and secondary care) and general practice records and randomised 2:1 to the BOOST programme or BPA. The primary outcome was the Oswestry Disability Index (ODI) at 12 months. Data was also collected at 6 months. Other outcomes included ODI walking item, 6-minute walk test (6MWT) and falls. The primary analysis was intention-to-treat.

Results: The average age of participants was 74.9 years (SD 6.0) and 57% (246/435) were female. There was no significant difference in ODI scores between treatment groups at 12 months (adjusted mean difference (MD): -1.4 [95% Confidence Intervals (CI) -4.03, 1.17]), but, at 6 months, ODI scores favoured the BOOST programme (adjusted MD: -3.7 [95% CI - 6.27, -1.06]). At 12 months, the BOOST programme resulted in greater improvements in walking capacity (6MWT MD 21.7m [95% CI 5.96, 37.38]) and ODI walking item (MD -0.2 [95% CI -0.45, -0.01]) and reduced falls risk (odds ratio 0.6 [95% CI 0.40, 0.98]) compared to BPA. No serious adverse events were related to either treatment.

Conclusions: The BOOST programme substantially improved mobility for older adults with NC. Future iterations of the programme will consider ways to improve long-term pain related disability.

Clinical Trials Registration: ISRCTN12698674

Keywords: spinal stenosis, rehabilitation, exercise, psychosocial, pain

Introduction

Neurogenic claudication (NC) is a common, debilitating spinal condition affecting older adults (1). It presents as pain, discomfort or other symptoms radiating from the spine into the buttocks and legs (2). Back pain is often present. Approximately 11% of community dwelling older adults report symptoms consistent with NC (3, 4). Symptoms are thought to arise from pressure on nerves and blood vessels in the spinal canal caused by degenerative narrowing of the spinal canal. The impact of narrowing is exacerbated by spinal position especially extension and symptoms are provoked by walking or standing and relieved by sitting or lumbar flexion (2). Narrowing may or may not be evident on imaging (1), and if present, the condition is termed Lumbar Spinal Stenosis. NC substantially affects an individual's confidence and ability to walk and is associated with adverse health outcomes and reduced quality of life (3, 5).

Despite the recognised severity of neurogenic claudication and LSS, there are insufficient numbers of high quality randomised controlled trials to inform clinical guidelines about the benefits of conservative interventions. In the absence of research evidence, two recent guidelines concluded that exercise/ physical therapy might be considered despite the effects on neurogenic pain not being known(6, 7). This lack of data extends to adverse outcomes of falls and muscle weakness. Behavioural interventions, including cognitive behavioural therapy have proven effective in managing non-specific low back pain and promoting physical activity (8), but have not been investigated in NC. Hence, the aim of the Better Outcomes for Older People with Spinal Trouble (BOOST) Trial was to estimate the clinical effectiveness of a physiotherapist delivered physical and psychological intervention for older adults with neurogenic claudication compared to best practice advice.

Method

Design

This study was a pragmatic, multicentre, randomised controlled superiority trial (RCT). The protocol, pre-specified statistical analysis plan and detailed description of the interventions are published elsewhere (9-11).

Participants

Community-dwelling adults, aged 65 years and over, who reported symptoms consistent with NC were eligible. Symptoms included a report of back pain and/or pain or other symptoms such as tingling, numbness or heaviness that travelled from their back into their buttocks or legs in the last 6 weeks. Standing or walking made symptoms in the buttocks or legs worse and/or sitting or bending forward relieved these symptoms. Exclusion criteria included nursing home residents, inability to walk 3 meters independently, awaiting surgery, cauda equina syndrome or signs of serious pathology, cognitive impairment and registered blind or unable to follow instructions in a group setting.

Potential participants were identified through community-based physiotherapy clinics and secondary care spinal clinics in 15 National Health Service (NHS) Trusts in England. Participants were also identified through a survey of general practices (The Oxford Pain, Activity and Lifestyle Survey [OPAL] cohort study)(12).

Once identified, potential participants were telephoned by a trained researcher (physiotherapist or nurse) for initial screening. If eligible and willing, potential participants attended an appointment to undergo an eligibility assessment conducted by the researcher. This included checking symptoms were consistent with NC and screening for cognitive impairment (defined as Abbreviated Mental Test score of 6 or less)(13) and serious pathology. All participants provided written informed consent prior to enrolment in the trial. Baseline data was then collected.

Randomisation and masking

We used a secure web-based service provided by the Oxford Clinical Trials Research Unit. Randomisation was stratified by recruitment centre, age (65-74 years and 75 years+), and gender, using variable, randomly selected block sizes of 3 and 6. Participants were randomised in a 2:1 ratio (intervention:control) to ensure that we could fill BOOST groups without participants experiencing long waiting times.

It was not possible to mask participants, physiotherapists delivering interventions or researchers assessing intervention fidelity. Participants were informed of their allocation at the first treatment session with the treating physiotherapist. Outcome assessors were masked to treatment allocation. During the conduct of the trial, the statistician had access to unmasked baseline summary data where required by the Data Monitoring Committee. The rest of the trial management team, including staff involved in data management, were masked to treatment allocation. Data cleaning and preparation of analysis code were undertaken by a masked statistician, and only once the data were formally locked, was the final analysis code run and allocation revealed.

The BOOST programme

The experimental intervention was a combined physical and psychological group programme (BOOST programme) delivered by a physiotherapist in twelve 90-minute group sessions over 12-weeks (11). Participants were asked to undertake a home exercise programme twice weekly during and beyond the formal programme.

First, each participant had an individual physiotherapy assessment. This included assessment of presenting NC symptoms, general health status and current activity levels including

walking ability and screening for serious pathology. Physiotherapists assessed the participants' ability to undertake the exercises to be completed during the group sessions and set the starting point for the exercises (sets, repetitions and load) and walking programme. This allowed individual tailoring. Four exercises targeted muscle strength (sitting knee extension, sit to stand, standing hip abduction and standing hip extension). We used the Borg Rating Scale of Perceived Exertion for strength training to guide exercise prescription with the aim of achieving an adequate stimulus to promote strength gains. Participants were encouraged them to work at level 5-6/10 on this scale (the exercise feels hard) (14). Exercises also targeted balance, and flexibility (hip flexor and calf stretch) whilst the walking circuit aimed to increase walking self-efficacy, dynamic balance and mobility.

Participants attended the supervised sessions twice a week for sessions 1-6, weekly for sessions 7-9 and fortnightly for sessions 10-12. The twice-weekly home exercises were introduced during session 5 enabling participants to undertake the exercises with support before continuing independently. One and two months after completing the supervised sessions, physiotherapists conducted telephone reviews to promote adherence with the home exercises. The telephone calls followed a checklist and identified barriers to independent exercises, facilitated problem solving and allowed the physiotherapist to provide additional tailoring of the programme as necessary.

Each group session followed the same format. The first 30 minutes was education and discussion based on a cognitive behavioural approach (CBA) to encourage adherence with the programme. This was followed by the exercise element which took approximately one hour. There was a short warm-up of seated exercises (arm raises, trunk rotation, pelvic tilting and knee lifts). Then participants completed their individually tailored strength, balance and flexibility exercises which were progressed over the 12 weeks. The strengthening exercises

were progressed by increasing the number of sets and repetitions, adding/increasing load or adding speed. These exercises were also the home exercises. Participants then undertook a 20-minute supervised walking circuit which was progressed by increasing the distance/time walked, increasing walking speed and adding challenges such as obstacles (stairs or walking outside) or adding weights. Participants were guided to gradually increase their walking distance during their home exercise programme.

The control intervention

The control intervention was best practice advice (BPA) delivered during individual physiotherapy appointments. The first appointment (60 minutes) included an assessment to tailor the advice and education provided. The assessment covered presenting NC symptoms, general health status and current activity levels, screening for serious pathology, spinal range of movement and walking ability. Verbal and written advice and education were provided including education about NC, being physically active, use of medications, when to seek more advice and, prescription of up to four home exercises. Flexion and trunk stabilisation were recommended but other exercises were allowed based on the assessment. If indicated, a walking aid was prescribed. Ideally, the control intervention was delivered in one session. If the physiotherapist felt it was necessary, then up to two review appointments were permitted (30 minutes each) to re-enforce advice and review exercises or walking aids. Physiotherapists could not provide treatments such as manual therapy, acupuncture or supervised exercise sessions.

All physiotherapists attended training in intervention delivery and trial procedures. Physiotherapists completed 2-3 hours of online training prior to attending a BOOST programme training day (7 hours). BPA training was delivered in 2-3 hours on a separate day. Physiotherapists completed a treatment log for each participant. The research team observed the intervention sessions to monitor intervention delivery. A structured checklist was used to assess the delivery of the core elements of interventions (Supplementary Table S1) which was scored as not completed, partially completed or fully completed. Initial observations were used to provide feedback and support physiotherapists to deliver the interventions. Later in the trial, these visits were fidelity assessments to understand how the intervention would be implemented in a real-world clinical setting with no feedback to the physiotherapists.

Data collection

Participants completed a questionnaire and a masked researcher conducted physical testing at baseline and 6 and 12 months after randomisation. If participants did not attend the follow up appointment, then the physical tests were not completed and participants were sent a postal questionnaire. If the questionnaire was not returned after two reminders, then the study team collected core outcomes over the telephone, where possible.

Baseline variables

Descriptive baseline data included demographic data, weight and height, self-reported comorbidities (based on (15), with multimorbidity defined as two or more health conditions (16)), other pain problems measured using the Nordic pain questionnaire (17), use of walking aids inside, self-rated walking speed (18) and change in mobility in the last year.

The STarT Back Screening Questionnaire was completed and participants categorised according to their risk (low, medium or high) of developing persistent, disabling symptoms (19). Baseline psychological factors included confidence to exercise (Exercise Self-efficacy Scale (short version)(20), confidence to manage their leg and back symptoms, intentions to carry out home exercises, walking self-efficacy (21) and fear-avoidance (Fear Avoidance Beliefs Questionnaire)(22). The Attitude to Ageing Questionnaire (physical changes subscale) was completed (23).

Outcome measures

Primary outcome

The primary outcome was the Oswestry Disability Index (ODI v2.1a, https://mapitrust.org/questionnaires/odi/) at 12 months after randomisation. This participant reported measure of pain related disability is scored 0-100 with a higher score indicating greater disability.

Secondary outcomes

Participants underwent physical testing including the six minute walk test (6MWT), Short Physical Performance Battery (SPPB, range 0-12, higher score indicates better physical performance)(24) and a measure of hand grip strength (25).

Patient reported walking disability was measured using the ODI walking item (range 0-5, higher score indicating greater disability). Physical activity was measured using two items from the Rapid Assessment Disuse Index (time moving on feet, time spent sitting; range 1-5, lower score indicates greater duration moving/sitting) (26).

Participant reported falls and related injuries were collected by recall over a 6 month period using methods recommended by the Prevention of Falls Network Europe (ProFANE) (27). Frailty was measured using the Tilburg Frailty Indicator (TFI) (range 0-15, higher score indicates greater frailty, physical subscale: range 0-8; psychological subscale: range 0-4) (28). Participant reported outcomes relating to symptoms were measured using the Swiss Spinal Stenosis Questionnaire symptom-severity scale (range 1-5, higher score indicates greater symptom severity) (29), pain troublesomeness scale (range 0-5, higher score indicates greater troublesomeness) (30) and global rating of change (range 0-6, lower score indicates improvement) (31). Satisfaction with changes in back and leg pain and satisfaction with treatment was measured using a 5-point scale constructed for the trial (range 0-4, higher score indicates greater satisfaction).

We collected adherence to home exercises via self-reported exercise frequency at follow-up, and adverse events related to the interventions (see supplementary materials for more information).

Sample size

At 80% power and 5% two-sided significance levels, a sample size of 321 participants (214 in the intervention group and 107 in the BPA group) was required. With an inflation for potential loss to follow-up (20%) this led to an overall target of 402 (268 intervention, 134 control). The sample size assumed a between-group difference of 5 points in the ODI to be clinically significant, with a baseline standard deviation (SD) of 15 (32).

Statistical analysis

The primary outcome of ODI at 12 months follow up was analysed in an intention-to-treat (ITT) population and effect estimates with their 95% confidence intervals (CI) were reported at a 0.05 significance level. The ODI difference between the two treatment groups was estimated using a repeated measures linear mixed-effects regression multilevel model with fixed effects for participant age, gender and baseline ODI, and random effects for recruiting centre and observations within-participant (6 and 12 months). To allow the treatment effect estimation at each follow-up time point, a treatment-by-time point interaction was also

included in the model, with time point treated as categorial. Missing items within scales were dealt with based on published instrument recommendations. All participants with baseline and at least one follow-up outcome value were included in the likelihood-based estimation of the mixed effects model in the analysis, under the missing at random assumption.

A model additionally accounting for potential heterogeneity due to the treating physiotherapist was assessed in a sensitivity analysis. As multiple physiotherapists delivered some BOOST groups, the physiotherapist delivering the highest number of sessions was selected for the model. Similarly, we assessed if there was a group effect by including the BOOST group attended by each participant in a separate model. The robustness of the primary analysis for the primary outcome among participants compliant with treatment was conducted using a complier average causal effect (CACE) analysis (33). Compliance with the BOOST programme was defined as attending at least 9 out of the 12 sessions (75%). Secondary outcomes were analysed in the ITT population, using similar model specifications for linear, logistic or ordinal logistic mixed effects regression models as appropriate and adjusting for the relevant baseline covariate where applicable. Analyses of secondary

outcomes were considered supportive of the primary outcome analysis. All analyses were carried out using STATA version 15.1 (StataCorp, College Station, TX, USA).

Ethical approval

Ethics approval for the BOOST trial was given by the London-Brent National Research Ethics Committee (REC number 16/LO/0349), on 03 March 2016.

Results

Participant flow is shown in Figure 1. Participants were recruited between 01 August 2016 and 29 August 2018 at 15 trial sites. Clinical staff identified 732 potential participants to undergo screening by researchers. From the OPAL cohort, we identified 152 potential participants. After screening, a total of 438 participants were eligible and willing to participate, provided informed consent and were randomised. Three participants withdrew after randomisation and removed consent data use (all allocated to BOOST programme, two withdrew before their first physiotherapy appointment, one withdrew after their first appointment). Therefore, 435 participants (BPA n=143, BOOST programme n=292) were included in the trial.

The primary outcome was obtained for 88.0% (383/435) and 87.4% (380/435) of participants at 6 months and 12 months respectively with 93.0% (403/435) contributing data to the primary analysis. During the follow up period, 6.2% (27/435) withdrew. The most common reason for withdrawal was health issues unrelated to their NC or the trial. There was no evidence of a differential loss to follow-up between the two groups. All reported deaths were found to be unrelated to the intervention.

Baseline characteristics

Participants had a mean age of 74.9 years (SD 6.0) and were predominantly white (91.9% (400/435)). The randomised groups were well matched on baseline characteristics (Table 1 and Table 2). In the BPA group, a larger proportion of participants were classified as frail (55.9% vs 44.5%) according to the Tilburg Frailty Index but other markers of frailty (6MWT, SPPB and hand grip strength) were similar. Eighty-one percent (351/435) had multimorbidity. The most commonly reported conditions were arthritis (272/435; 62.5%), high blood pressure (252/435; 57.9%), angina/heart problems (104/435; 23.9%), digestive problems (87/435; 20.0%) and diabetes (73/435; 16.8%).

Intervention delivery

Sixty-nine physiotherapists delivered the interventions. Thirty physiotherapists delivered BPA, 34 physiotherapists delivered the BOOST programme and 5 physiotherapists delivered both. In total, 24/143 (16.8%) participants allocated to BPA were treated by physiotherapists who were also trained in the BOOST intervention.

Of the 143 participants allocated to BPA, 140 (98%) received the intervention. The mean time from randomisation to the first BPA appointment was 34.7 (SD 20.8) days. Most commonly, participants attended two BPA appointments (41.3% (59/143)). The reasons that three participants did not attend any appointments were health problems, family concerns and a decision to have spinal surgery.

Of the 292 participants allocated to the BOOST programme, 279 (96.0%) attended the individual physiotherapy assessment (mean time from randomisation to appointment: 31.2 (SD 27.3) days). Thirteen participants (4.5%) did not attend this assessment. Reasons for non-attendance included sickness, lack of time, travel distance, work commitments, group allocation and considering surgery. After the individual assessment, participants joined the next available group (mean time from randomisation to the first group session: 58.7 (SD 38.51) days). In total, 203/292 (69.5%) attended at least 9 of the 12 sessions indicating compliance. Having attended the individual assessment, 13 participants (4.5%) subsequently did not attend any group sessions. The most common reasons for group non-attendance were holidays or sickness.

We conducted 123 observations of treatment sessions including 48 fidelity assessments. Interventions were delivered to a high standard. Eighteen fidelity assessments were undertaken of BPA sessions and 97.2% of check list items were fully achieved. Thirty fidelity assessments of the BOOST programme group sessions were conducted with 97.4% of check list items fully achieved. Monitoring of treatment logs showed that exercises were progressed regularly across the key parameters including increased repetitions and load, and addition of speed to the strengthening exercises. During the walking circuit, increasingly difficult elements were added to challenge balance such as increased speed, carrying weights and negotiating obstacles.

Primary outcome

Participants randomised to BPA showed a small increase in ODI scores at 6 months with very little subsequent change at 12 months. BOOST programme participants showed a reduction in ODI scores at 6 months which increased again at 12 months but remained lower than baseline scores. At the 12-month primary end point, there was no statistically significant difference in ODI scores between the two treatment groups (adjusted mean difference -1.4, 95% CI -4.03 to 1.17). There was a statistically significant difference in ODI in favour of the BOOST Programme group (adjusted mean difference -3.7, 95% CI -6.27 to -1.06) at 6 months. There was no evidence of a therapist or group effect.

In the CACE analysis, the difference favouring the BOOST programme was larger, reaching the pre-defined clinically significant threshold (5 points on the ODI) when group attendance was taken into consideration (-5.0, 95% CI -8.02 to -1.88) at 6 months. At 12 months, this difference was reduced (-2.4, 95% CI -6.02 to 1.32). Amongst non-compliers there was a greater proportion characterised as frail (50.6% versus 41.9%), having fallen in the previous year (43.8% versus 37.4%), and reporting very/extremely troublesome back and leg pain (57.3% versus 51.2%) compared to compliers.

Secondary outcomes (Tables 2 and 3)

The BOOST programme had a lasting impact on walking capacity (6MWT) (Figure 2) at 6 and 12 months follow up favouring the BOOST programme. BPA participants showed very little change across the two follow up time points. A similar response was observed for physical performance (SPPB). Changes in grip strength favoured the BOOST programme at 6 months but there was no between group difference at 12 months.

The BOOST programme reduced walking disability (ODI walking item) at 6 and 12 months compared to BPA. BOOST participants were more likely to spend more time on their feet at 6 months but not 12 months. There was no impact on time spent sitting.

BOOST programme participants had a substantially reduced risk of reporting a fall over the 12-month period. The proportion of participants reporting a fracture following a fall was very small but similar between groups. Physical frailty scores favoured the BOOST programme (TFI physical subscale) at 6 months with BOOST participants demonstrating less decline than the BPA group. There was no difference at 12 months. There was no impact on overall TFI or psychological subscale.

Both groups reported a small reduction in SSS symptoms subscale scores at 6 months and these were larger for the BOOST programme. Small reductions were maintained at 12 months and there was no longer a difference between the groups at 12 months. Similar findings were observed for troublesomeness, Global Rating of Change and satisfaction with changes in back and leg problems. BOOST programme participants were more likely to be satisfied with their treatment at 6 and 12 months compared to the control group.

Exercise adherence

Participants were asked how often they performed their home exercises. At 6 months, 190/257 (73.9%) BOOST programme participants reported performing their exercises at least twice per week which reduced to 143/250 (57.2%) at 12 months. At 6 months, 102/125 (81.6%) BPA participants reported doing their exercises at least twice a week which reduced to 89/125 (71.2%) at 12 months.

Adverse events

One serious adverse event (cardiac symptoms) occurred during a BOOST group session which was deemed unrelated to the intervention. There were no serious adverse events reported for BPA. There were 12 adverse events reported for the BOOST Programme (Supplementary Table S2). Four were assessed as definitely related to the programme including aggravation of joint pains (n=2), a fall during the walking circuit (no injuries) and skin irritation by an ankle weight. Two adverse events were reported for BPA and neither were definitely related to the treatment.

Discussion

The BOOST programme improved walking capacity and physical performance and reduced walking disability and falls risk compared to a control intervention of BPA for older adults with NC at 12 months follow up. There were also improvements in pain related disability at 6 months favouring the BOOST programme but only a small difference between groups was maintained at 12 months which was not statistically significant. Symptom reduction followed a similar pattern. There was very little change in the scores of BPA participants for outcomes generally over time.

The biggest impact was on mobility. Baseline walking distances were well below published values for healthy older people demonstrating the substantial impact that NC has on walking ability (34). The mean baseline 6MWT distances for BOOST participants were lower than other published baseline values of NC cohorts (for example, (35) baseline 6MWT 315m, mean age=67 years) but BOOST participant were older. As people age, we expect a decline in walking over time rather than improvement (36), yet, participants attending the BOOST programme demonstrated changes in walking capacity with observed improvements within the published values for clinically important differences for the 6MWT (37). These

improvements were not observed in BPA participants who changed very little. Chronic pain, such as that experienced from NC, which is a chronic degenerative condition, is associated with falls in older people (38). The BOOST programme reduced falls risk by approximately 40% over 12 months which is more effective than most community based falls prevention programmes (39). These lasting improvements in mobility and reduced falls risk are important outcomes for older adults. Active independence is one of the key concerns of older people, and maintaining mobility is integral to this (40). Qualitative research demonstrates a desire by older people to improve their walking even if they cannot alleviate the pain of NC (41). Despite the value of mobility to older people, its importance as an outcome in clinical trials of treatments of NC or spinal stenosis is often overlooked, especially in surgical trials. Two recent network meta-analyses of treatments for spinal stenosis evaluated effectiveness solely on pain and disability, failing to evaluate the impact on walking (42, 43). An exception to this is a surgical trial currently being conducted which has chosen improvement in walking capacity as the co-primary outcome along with the ODI (44).

The short-term reduction in pain related disability among BOOST participants compared to BPA suggests that while participants are engaged with the programme it effectively reduces pain related disability. The between group difference increased when group attendance is taken into account. However, when the intervention stops, the impact on pain related disability reduces. Although, participants were still capable of walking further (6MWT improvements were maintained), it no longer translates into reduced pain related disability. We noted a reduction in independent exercise in the BOOST Group between 6 and 12 months follow up which may explain why improvements were not maintained. This finding is not unique to the BOOST programme. Devereux-Fitzgerald et al (45) found supervision by a health professional increases the perceived value of physical activity interventions enhancing engagement but this reduces when supervision ceases. Attendance at a group is enjoyable and provides increased social connections, but solo activities such as independent exercise are often considered boring leading to lack of motivation (45). Self-reported adherence with the home exercises was better in the BPA group who were given a less intensive home exercise programme (up to four spinal mobility and/or stability exercise). BOOST participants may have perceived their home exercise as too onerous, and consideration should be given as to whether the unsupervised element of the programme can be optimised to maximise adherence. It may also be that participants experience a flare up of their pain which is common in NC. We used a less intensive CBA than a previous trial evaluating a CBA (Back Skills Training Programme (8)) which effectively reduced back pain related disability longterm so this element of the BOOST programme could be enhanced to assist participants to deal with increases in pain.

Three trials of note were recently published (46-49). Similar to the BOOST trial, all tested programmes which included structured and progressive exercises to improve trunk and lower limb mobility, strength and fitness. Participants also received manual therapy treatment to increase spinal movement. The Ammendolia programme is most similar to the BOOST programme including a CBA for pain management and structured walking programme delivered over 12 sessions (47). It was compared to self-directed exercise (one session). The Ammendolia programme also resulted in lasting improvements in walking compared to the control providing further support for implementing these types of programme. The 6-week (12 sessions) programme evaluated by Minetama also included walking training which was done on a treadmill but did not address any psychological factors (48, 49). It resulted in superior outcomes across multiple domains (walking, pain, function) on completion of treatment compared to home exercises (48). Some benefits were retained at 12 months follow

up in regard to pain and function but unfortunately, they did not measure walking (49). The Schneider programme did not have a focused walking element or use a CBA (46). This threearm study found no difference in walking between the 6-week experimental arm and control arm of medical care, suggesting one or both of these elements are important to achieve walking improvements.

Ensuring effective treatments are available to older people with NC is very important as, currently, treatment options are limited. There is little evidence supporting the use of medication (50). Careful consideration is needed before prescribing medication for older people due to potential side effects including falls (50). Surgery is an option with symptomatic spinal stenosis being the most common reason for spinal surgery in older adults (51). However, the effectiveness of surgery is unclear, and it exposes older people to considerable risk including wound infections, dural tears and cardiorespiratory complications in surgical trials are considerably younger (42). Our participants had a mean age of 75 years, the majority were multimorbid and nearly half were frail. The BOOST programme should be considered a worthwhile conservative treatment for older adults especially when they are not surgical candidates or face long waiting times for surgery due to the impact of the COVID-19 pandemic on NHS waiting lists.

We believe our trial to have considerable strengths. It was a pragmatic trial conducted across a range of NHS settings. We recruited participants from general practice, community-based physiotherapy clinics and spinal clinics in secondary care hospitals lending to the generalisability of findings. Based on fidelity assessments, the BOOST programme can be delivered to a high standard in different settings. The questions used to identify those with NC are commonly used in clinical practice and been shown to have high sensitivity and specificity to identify people with symptoms arising from spinal stenosis (1). This makes it easy for clinicians to identify people that would be suitable for the programme without the need for MRI. The BOOST programme was well received by participants and despite the required commitment, the programme was well attended. However, compliance was lower amongst participants who were frail, reported falling and had more troublesome symptoms. These individuals may require more support and encouragement to attend the programme.

A limitation of the study is that five physiotherapists trained in delivery of the BOOST programme also treated 24/143 participants (16.8%) allocated to BPA due to physiotherapist availability. However, the proportion of participants in the control arm exposed to potential contamination is well below the 30% threshold considered a serious threat (53). We carefully monitored intervention delivery using treatment logs and observation sessions to ensure the standardised protocols were followed. From fidelity assessments, we are confident that the risk of contamination between arms was minimised. We took all possible steps to mask the trial team, outcome assessors and statisticians. It is possible that during the final analysis statisticians could deduce the allocation because of the unequal randomisation, but at that stage the database was securely locked, and data could not be tampered with or changed.

There are some potential limitations related to the interventions. Firstly, we used the Borg Rating of Perceived Exertion to prescribe the BOOST programme strengthening exercises. This is a pragmatic approach to exercise prescription that can be done easily in a clinical setting and is recommended as a suitable approach for prescribing resistance training for older adults (54). However, this approach may not be as accurate as using a method based on a percentage of one repetition maximum (%1RM) with the risk of under or over-dosing. Finally, the participants attending the BOOST programme had more contact time with the treating physiotherapist than those attending BPA. As this was a pragmatic trial, we did not account for this in our control intervention and using an attention control, such as that used by LaFave et al (55), would have enabled us to disentangle the benefits of attention from the impact of the BOOST programme.

The BOOST programme could be optimised to maintain the impact on pain related disability. In particular, strategies for improving long-term exercise adherence should be considered including additional support. Additional support could include booster sessions which has been shown to increase exercise adherence in populations with back pain and osteoarthritis (56). We will also consider enhancing the CB element to improve pain management. We plan to undertake further analysis of the BOOST data set to increase our understanding of participants' response to the intervention and to understand the mechanisms of action including mediation analyses (57).

In conclusion, the BOOST programme improves mobility and reduces falls for older adults with NC compared to BPA at 12 months. With limited treatment options available to older people with NC, implementation of the programme should be considered. Future iterations of the programme will consider ways to improve long-term pain related disability.

Funding

This research was funded by the NIHR Programme Grants for Applied Research (reference: PTC-RP-PG-0213-20002). This research was supported by the National Institute for Health Research Applied Research Collaboration Oxford and Thames Valley at Oxford Health NHS Foundation Trust. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Conflict of Interest

None declared.

Acknowledgments

Thank you to the BOOST research group for their assistance with undertaking this study.

BOOST programme co-applicants, researchers and trial management staff: Mandy Maredza, Stavros Petrou, Julie Bruce, Frances Griffith, Gary Collins, Charles Hutchinson, Richard Gagen, Mandy Slack and Oliver Conway.

Patient and Public Involvement Representatives: Judith Fitch, Eileen Turner and John Arden Data Monitoring and Ethics Committee: David Torgerson (Chair), Catherine Sackley, Candy McCabe.

Programme Steering Committee: Stephanie Taylor (Chair), Catherine Hewitt, Anne Forster, Lindsey Bearne, Jim Watson (PPI representative).

Clinical Collaborators:

Birmingham Community NHS Trust: Lindsey Hurley (Principal Investigator [PI]), Claire Williams, Connor Ruffinato, Emma Komocki, Joe Golby, Jonathan Price, Lauren Shields, Lorraine Moylan, Rowena Quirk. Cambridgeshire Community Services NHS Trust: Jenny Van Maurik (PI), Ben Whybrow, Greg Wisniewski, Mandy Whitlock, Matthew Pearson, Michelle Read, Ben Whybrow, Michelle Read, Oliver Richardson, Rachel Renshaw.

Croydon Health Services NHS Trust: Suzy Peerman (PI), Brinna Robertson-More, Emma Parker, Georgia Leher, Hilary Viggars, Lee McFarland, Louise Robles, Lynette Boot.

Dorset Healthcare University NHS Foundation Trust: Katrina Kennedy (PI), Christian Verrinder (PI) Brandon Bule, Chris Mott, Emma Bell, Josephine Moore, Kate Gough, Kathryn Francis, Louise Kazemi, Louise Pearce, Susan Dowdle.

East Cheshire NHS Trust: Simon Hogan (PI), Helen Ashton, Helen Lomas, Kerry Wallis, Laura Plant, Richard Saxton, Vicki Austin.

Gloucestershire Care Services NHS Trust: Caroline Hooper (PI), Emma Moule, Helen Fursman, Inge Carrington, Jo Godley, Karen McIlveen, Sherry Claridge.

Leeds Community NHS Healthcare Trust: Christine Comer (PI), John O'Hora, Sam Noble, Samantha Kelly, Stephen Bell.

Leeds Teaching Hospital NHS Trust: Denise Ross (PI), Joanne Draycott, Tom Bindloss.

Northwest Boroughs Partnership NHS Trust: Gill Dickson (PI), Aisling McGrath, Catherine Atherton, Catherine Quigley, Ceit Bannon, Emma Painter, Joanna Lunt, Matthew Martyniak, Paula Cleary, Peter Cuddy, Rebecca McDonough.

Oxford University Hospitals NHS Foundation Trust: Karen Barker (PI), Amanda Robertson, Bridget Gould, Claire Rogers, Colette Tracey, Helen Stevens, Jack Martin, James Pollard, Lindsay Cummings, Louise Laleye, Martha Batting, Michelle Moynihan, Monika Tomizcek, Ryan Kelsall, Sam Collins, Tamsin Hughes Royal Liverpool NHS Trust: Lynda Gibson (PI), Caroline Morrish, Catherine Heaton, Kerry Mclean

Salisbury NHS Foundation Trust: Alison Wright (PI), Claire Fry, Claire Paling, Craig Evans, Karen Jocelyn, Kate Josling

Sandwell & West Birmingham NHS Trust: Felipe Forte (PI), Anju Bhopal, Beena Borhara, Emma Fletcher, Hannah Brown, Leah O'Toole, Natasha Pathak, Sarah Calloway, Yogita Stokes

The Royal Orthopaedic Hospital NHS Foundation Trust: Adrian Gardener (PI), Claudette Jones, Dave Rogers, Gareth Stephens, Jodie Walters, Kate MacFarlane, Lucie Gosling, Natalie Jackson, Sarah Rich, Sue Thomas

Wirral University Teaching Hospital NHS Trust: Carole Burton (PI), Zara Hansen (PI), Clare Greenwood, Dan Hopwood, Gareth Hunt, Helen Westcott, Lynne Hardy, Robbie Ryan, Stewart Langford

This study has been conducted as part of the portfolio of trials in the registered UKCRC Oxford Clinical Trials Research Unit (OCTRU) at the University of Oxford. It has followed their Standard Operating Procedures ensuring compliance with the principles of Good Clinical Practice and the Declaration of Helsinki and any applicable regulatory requirements.

Author Contributions

EW is the lead author of this manuscript. IRM, SD and SL were involved in writing the manuscript. All authors have reviewed and approved the final manuscript. SL is the Chief Investigator, senior author and the guarantor. EW, KB, JB, JF, DF, ZH, CM are co-applicants on the grant awarded by the NIHR Programme Grants for Applied Research and were involved in the design of the study and its implementation, as were AG as trial manager, AM

as a research associate, SD and IRM as trial statisticians, GB and PN as research physical therapists and LW as a health researcher. DR and CC provided specialist physical therapy input.

k contraction

References

 de Schepper EI, Overdevest GM, Suri P, Peul WC, Oei EH, Koes BW, et al.
 Diagnosis of Lumbar Spinal Stenosis: An Updated Systematic Review of the Accuracy of Diagnostic Tests. Spine (Phila Pa 1976). 2013;38(8):E469-E81.

https://doi.org/10.1097/brs.0b013e31828935ac.

2. Suri P, Rainville J, Kalichman L, Katz JN. Does this older adult with lower extremity pain have the clinical syndrome of lumbar spinal stenosis? JAMA. 2010;304(23):2628-36. https://doi.org/10.1001/jama.2010.1833.

3. Williamson E, Sanchez Santos MT, Morris A, Garrett A, Conway O, Boniface G, et al. The Prevalence of Back and Leg Pain and the Cross-sectional Association With Adverse Health Outcomes in Community Dwelling Older Adults in England. Spine (Phila Pa 1976). 2021;46(1):54-61. https://doi.org/10.1097/brs.00000000003719.

Ishimoto Y, Yoshimura N, Muraki S, Yamada H, Nagata K, Hashizume H, et al.
Prevalence of symptomatic lumbar spinal stenosis and its association with physical performance in a population-based cohort in Japan: the Wakayama Spine Study.
Osteoarthritis Cartilage. 2012;20(10):1103-8. https://doi.org/10.1016/j.joca.2012.06.018.

5. Battié MC, Jones CA, Schopflocher DP, Hu RW. Health-related quality of life and comorbidities associated with lumbar spinal stenosis. Spine J. 2012;12(3):189-95. https://doi.org/10.1016/j.spinee.2011.11.009.

6. Kreiner DS, Shaffer WO, Baisden J, Gilbert T, Summers J, Toton J, et al. Evidencebased clinical guidelines for multidisciplinary spine care: diagnosis and treatment of degenerative lumbar spinal stenosis. North American Spine Society; 2011. https://doi.org/10.1016/j.spinee.2012.11.059.

Rousing R, Jensen RK, Fruensgaard S, Strøm J, Brøgger HA, Degn JDM, et al.
 Danish national clinical guidelines for surgical and nonsurgical treatment of patients with

lumbar spinal stenosis. Eur Spine J. 2019;28(6):1386-96. https://doi.org/10.1007/s00586-019-05987-2.

8. Lamb S, Hansen Z, Lall R, Castelnuovo E, Withers E, Nichols V, et al. Group cognitive behavioural treatment for low-back pain in primary care: a randomised controlled trial and cost-effectiveness analysis. Lancet. 2010;375(9718):916-23.

https://doi.org/10.1016/s0140-6736(09)62164-4.

9. Williamson E, Ward L, Vadher K, Dutton SJ, Parker B, Petrou S, et al. Better Outcomes for Older people with Spinal Trouble (BOOST) Trial: a randomised controlled trial of a combined physical and psychological intervention for older adults with neurogenic claudication, a protocol. BMJ Open. 2018;8(10):e022205. http://dx.doi.org/10.1136/bmjopen-2018-022205.

10. Marian IR, Williamson E, Garrett A, Lamb SE, Dutton SJ. Better Outcomes for Older people with Spinal Trouble (BOOST) trial: statistical analysis plan for a randomised controlled trial of a combined physical and psychological intervention for older adults with neurogenic claudication. Trials. 2020;21(1):667. https://doi.org/10.1186/s13063-020-04590-x.

 Ward L, Williamson E, Hansen Z, French DP, Boniface G, Rogers D, et al.
 Development and delivery of the BOOST (Better Outcomes for Older adults with Spinal Trouble) intervention for older adults with neurogenic claudication. Physiotherapy.
 2019;105(2):262-74. https://doi.org/10.1016/j.physio.2019.01.019.

12. Sanchez Santos MT, Williamson E, Bruce J, Ward L, Mallen CD, Garrett A, et al. Cohort profile: Oxford Pain, Activity and Lifestyle (OPAL) Study, a prospective cohort study of older adults in England. BMJ Open. 2020;10(9):e037516.

https://doi.org/10.1136/bmjopen-2020-037516.

Sheehan B. Assessment scales in dementia. Ther Adv Neurol Disord. 2012;5(6):349 https://doi.org/10.1177/1756285612455733.

14. Buckley JP, Borg GA. Borg's scales in strength training; from theory to practice in young and older adults. Appl Physiol Nutr Metab. 2011;36(5):682-92.

https://doi.org/10.1139/h11-078.

15. Chaudhry S, Jin L, Meltzer D. Use of a self-report-generated Charlson Comorbidity Index for predicting mortality. Med Care. 43. United States2005. p. 607-15. https://doi.org/10.1097/01.mlr.0000163658.65008.ec.

 Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring multimorbidity: a systematic review of systematic reviews. Eur J Public Health.
 2019;29(1):182-9. https://doi.org/10.1093/eurpub/cky098.

Kuorinka I, Jonsson B, Kilbom A, Vinterberg H, Biering-Sorensen F, Andersson G, et al. Standardised Nordic questionnaires for the analysis of musculoskeletal symptoms. Appl Ergon. 1987;18(3):233-7. https://doi.org/10.1016/0003-6870(87)90010-x.

18. Syddall HE, Westbury LD, Cooper C, Sayer AA. Self-reported walking speed: a useful marker of physical performance among community-dwelling older people? J Am Med Dir Assoc. 2015;16(4):323-8. https://doi.org/10.1016/j.jamda.2014.11.004.

 Hill JC, Dunn KM, Lewis M, Mullis R, Main CJ, Foster NE, et al. A primary care back pain screening tool: identifying patient subgroups for initial treatment. Arthritis Rheum. 2008;59(5):632-41. https://doi.org/10.1002/art.23563.

20. Resnick B, Jenkins LS. Testing the reliability and validity of the Self-Efficacy for Exercise scale. Nurs Res. 2000;49(3):154-9. https://doi.org/10.1097/00006199-200005000-00007.

21. Newell AM, VanSwearingen JM, Hile E, Brach JS. The modified Gait Efficacy Scale: establishing the psychometric properties in older adults. Phys Ther. 2012;92(2):318-28. https://doi.org/10.2522/ptj.20110053.

22. Waddell G, Newton M, Henderson I, Somerville D, Main CJ. A Fear-Avoidance Beliefs Questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and disability. Pain. 1993;52(2):157-68. https://doi.org/10.1016/0304-3959(93)90127-b.

23. Laidlaw K, Power MJ, Schmidt S. The Attitudes to Ageing Questionnaire (AAQ): development and psychometric properties. Int J Geriatr Psychiatry. 2007;22(4):367-79. https://doi.org/10.1002/gps.1683.

24. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85-94. https://doi.org/10.1093/geronj/49.2.m85.

25. Roberts HC, Syddall HE, Cooper C, Aihie Sayer A. Is grip strength associated with length of stay in hospitalised older patients admitted for rehabilitation? Findings from the Southampton grip strength study. Age Ageing. 2012;41(5):641-6.

https://doi.org/10.1093/ageing/afs089.

26. Shuval K, Kohl HW, 3rd, Bernstein I, Cheng D, Pettee Gabriel K, Barlow CE, et al. Sedentary behaviour and physical inactivity assessment in primary care: the Rapid Assessment Disuse Index (RADI) study. Br J Sports Med. 2014;48(3):250-5. https://doi.org/10.1136/bjsports-2013-092901.

27. Lamb SE, Jørstad-Stein EC, Hauer K, Becker C, Group PoFNEaOC. Development of a common outcome data set for fall injury prevention trials: the Prevention of Falls Network Europe consensus. J Am Geriatr Soc. 2005;53(9):1618-22. https://doi.org/10.1111/j.1532-5415.2005.53455.x.

28. Gobbens RJ, van Assen MA, Luijkx KG, Wijnen-Sponselee MT, Schols JM. The Tilburg Frailty Indicator: psychometric properties. J Am Med Dir Assoc. 2010;11(5):344-55. https://doi.org/10.1016/j.jamda.2009.11.003.

29. Cleland JA, Whitman JM, Houser JL, Wainner RS, Childs JD. Psychometric
properties of selected tests in patients with lumbar spinal stenosis. Spine J. 2012;12(10):92131. https://doi.org/10.1016/j.spinee.2012.05.004.

30. Underwood MR, Barnett AG, Vickers MR. Evaluation of two time-specific back pain outcome measures. Spine. 1999;24(11):1104-12. https://doi.org/10.1097/00007632-199906010-00010.

31. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17(3):163-70. https://dx.doi.org/10.1179%2Fjmt.2009.17.3.163.

32. Pua YH, Cai CC, Lim KC. Treadmill walking with body weight support is no more effective than cycling when added to an exercise program for lumbar spinal stenosis: a randomised controlled trial. Aust J Physiother. 2007;53(2):83-9.

https://doi.org/10.1016/s0004-9514(07)70040-5.

33. Dunn G, Maracy M, Tomenson B. Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res. 2005;14(4):369-95.

https://doi.org/10.1191/0962280205sm403oa.

34. Bohannon RW. Six-Minute Walk Test: A Meta-Analysis of Data From Apparently Healthy Elders. Topics in Geriatric Rehabilitation. 2007;23(2).

https://doi.org/10.1097/01.TGR.0000270184.98402.ef.

35. Försth P, Ólafsson G, Carlsson T, Frost A, Borgström F, Fritzell P, et al. A

Randomized, Controlled Trial of Fusion Surgery for Lumbar Spinal Stenosis. N Engl J Med. 2016;374(15):1413-23. http://doi.org/10.1056/NEJMoa1513721.

36. Ferrucci L, Cooper R, Shardell M, Simonsick EM, Schrack JA, Kuh D. Age-Related Change in Mobility: Perspectives From Life Course Epidemiology and Geroscience. J Gerontol A Biol Sci Med Sci. 2016;71(9):1184-94. https://doi.org/10.1093/gerona/glw043.

37. Bohannon RW, Crouch R. Minimal clinically important difference for change in 6minute walk test distance of adults with pathology: a systematic review. J Eval Clin Pract. 2017;23(2):377-81. https://doi.org/10.1111/jep.12629.

 Leveille SG, Jones RN, Kiely DK, Hausdorff JM, Shmerling RH, Guralnik JM, et al. Chronic musculoskeletal pain and the occurrence of falls in an older population. JAMA.
 2009;302(20):2214-21. https://doi.org/10.1001/jama.2009.1738.

39. Sherrington C, Fairhall NJ, Wallbank GK, Tiedemann A, Michaleff ZA, Howard K, et al. Exercise for preventing falls in older people living in the community. Cochrane Database of Systematic Reviews. 2019(1). https://doi.org/10.1002/14651858.CD012424.pub2.

40. Troutman-Jordan M, Staples J. Successful aging from the viewpoint of older adults. Research and theory for nursing practice. 2014;28(1):87-104. https://doi.org/10.1891/1541-6577.28.1.87.

41. Lyle S, Williamson E, Darton F, Griffiths F, Lamb SE. A qualitative study of older people's experience of living with neurogenic claudication to inform the development of a physiotherapy intervention. Disabil Rehabil. 2017;39(10):1009-17.

https://doi.org/10.1080/09638288.2016.1177611.

42. Ma H, Hai B, Yan M, Liu X, Zhu B. Evaluation of Effectiveness of Treatment Strategies for Degenerative Lumbar Spinal Stenosis: A Systematic Review and Network Meta-Analysis of Clinical Studies. World Neurosurgery. 2021;152:95-106. https://doi.org/10.1016/j.wneu.2021.06.016.

43. Wei FL, Zhou CP, Liu R, Zhu KL, Du MR, Gao HR, et al. Management for lumbar spinal stenosis: A network meta-analysis and systematic review. Int J Surg. 2021;85:19-28. https://doi.org/10.1016/j.ijsu.2020.11.014.

44. Anderson DB, Ferreira ML, Harris IA, Davis GA, Stanford R, Beard D, et al.
SUcceSS, SUrgery for Spinal Stenosis: protocol of a randomised, placebo-controlled trial.
2019;9(2):e024944. https://doi.org/10.1136/bmjopen-2018-024944.

45. Devereux-Fitzgerald A, Powell R, Dewhurst A, French DP. The acceptability of physical activity interventions to older adults: A systematic review and meta-synthesis. Soc Sci Med. 2016;158:14-23. https://doi.org/10.1016/j.socscimed.2016.04.006.

46. Schneider MJ, Ammendolia C, Murphy DR, Glick RM, Hile E, Tudorascu DL, et al.
Comparative Clinical Effectiveness of Nonsurgical Treatment Methods in Patients With
Lumbar Spinal Stenosis: A Randomized Clinical Trial. JAMA Netw Open.
2019;2(1):e186828. https://doi.org/10.1001/jamanetworkopen.2018.6828.

47. Ammendolia C, Côté P, Southerst D, Schneider M, Budgell B, Bombardier C, et al.
Comprehensive Nonsurgical Treatment Versus Self-directed Care to Improve Walking
Ability in Lumbar Spinal Stenosis: A Randomized Trial. Arch Phys Med Rehabil.
2018;99(12):2408-19.e2. https://doi.org/10.1016/j.apmr.2018.05.014.

48. Minetama M, Kawakami M, Teraguchi M, Kagotani R, Mera Y, Sumiya T, et al. Supervised physical therapy vs. home exercise for patients with lumbar spinal stenosis: a randomized controlled trial. Spine J. 2019;19(8):1310-8.

https://doi.org/10.1016/j.spinee.2019.04.009.

49. Minetama M, Kawakami M, Teraguchi M, Kagotani R, Mera Y, Sumiya T, et al. Supervised physical therapy versus unsupervised exercise for patients with lumbar spinal stenosis: 1-year follow-up of a randomized controlled trial. Clin Rehabil. 2021;35(7):964-75. https://doi.org/10.1177/0269215520986688.

Jensen RK, Harhangi BS, Huygen F, Koes B. Lumbar spinal stenosis. BMJ.
 2021;373:n1581. https://doi.org/10.1136/bmj.n1581.

51. Deyo RA, Mirza SK, Martin BI, Kreuter W, Goodman DC, Jarvik JG. Trends, major medical complications, and charges associated with surgery for lumbar spinal stenosis in older adults. JAMA. 2010;303(13):1259-65. https://dx.doi.org/10.1001%2Fjama.2010.338.

52. Zaina F, Tomkins-Lane C, Carragee E, Negrini S. Surgical versus non-surgical treatment for lumbar spinal stenosis. Cochrane Database Syst Rev. 2016(1):Cd010264. https://doi.org/10.1002/14651858.cd010264.pub2.

53. Torgerson DJ. Contamination in trials: is cluster randomisation the answer? BMJ (Clinical research ed). 2001;322(7282):355-7. https://doi.org/10.1136/bmj.322.7282.355.

54. Hurst C, Robinson SM, Witham MD, Dodds RM, Granic A, Buckland C, et al.
Resistance exercise as a treatment for sarcopenia: prescription and delivery. Age Ageing.
2022;51(2). https://doi.org/10.1093/ageing/afac003.

55. LaFave SE, Granbom M, Cudjoe TKM, Gottsch A, Shorb G, Szanton SL. Attention control group activities and perceived benefit in a trial of a behavioral intervention for older adults. Res Nurs Health. 2019;42(6):476-82. https://doi.org/10.1002/nur.21992.

56. Nicolson PJA, Bennell KL, Dobson FL, Van Ginckel A, Holden MA, Hinman RS. Interventions to increase adherence to therapeutic exercise in older adults with low back pain and/or hip/knee osteoarthritis: a systematic review and meta-analysis. British Journal of Sports Medicine. 2017;51(10):791. https://doi.org/10.1136/bjsports-2016-096458.

57. Comer C, Lee H, Williamson E, Lamb S. Understanding the mechanisms of a combined physical and psychological intervention for people with neurogenic claudication:

protocol for a causal mediation analysis of the BOOST trial. BMJ Open.

2020;10(9):e037121. https://doi.org/10.1136/bmjopen-2020-037121.

k certe

Repie

Figure 2 Marginal adjusted mean Six Minute Walk Test Results from baseline to 12 months by treatment group

		BPA (n = 143)	BOOST programme (n = 292)	Overall (n = 435)
Variables [#]			(n – -) -)	
Age (years) at baseli Female	ne	75.0 (5.6) 83 (58.0%)	74.8 (6.2) 163 (55.8%)	74.9 (6.0) 246
White ethnicity		132 (92.3%)	268 (91.8%)	(56.6%) 400 (91.9%)
Relationship status:				291
Married/Civil Union	/Cohabiting	97 (67.8%)	194 (66.40%)	(66.9%)
	arried/ Separated/Divorced	. ,	31 (10.7%)	47 (10.8%)
	Widow/Widower	· · ·	67 (22.9%)	97 (22.3%)
Care requirements:	Has an unpaid	31 (21.7%)	54 (18.5%)	85 (19.5%)
carer	Has a paid care	r 6 (4.2%)	10 (3.4%)	16 (3.7%)
Work status:	Thas a paid care	125 (87.4%)	263 (90.1%)	388
Retired		123 (87.470)	203 (90.170)	(89.2%)
	Working (full or part-time)) 10 (6.9%)	24 (8.2%)	34 (7.8%)
Education: education	None or primary	4 (2.8%)	18 (6.2%)	22 (5.1%)
education	Secondary education	n 80 (55.9%)	170 (58.2%)	250
	, in the second s			(57.5%)
Higher profess	sional/university education	n 59 (41.3%)	104 (35.6%)	163 (37.5%)
Smoking status:	Never	61 (42.7%)	136 (46.6%)	197
smoked				(45.3%)
	Former smoker	r 75 (52.4%)	140 (47.9%)	215
		\overline{a}		(49.4%)
	Current smoker	· · · ·	16 (5.5%)	23 (5.3%)
Body Mass Index		30.0 (5.4)	29.9 (4.8)	29.9 (5.0)
(IQR)	lities reported, median	3 (2, 4)	2 (2,4)	2 (2,4)
Nordic pain question pain	naire: Single-site	14 (9.8%)	16 (5.5%)	30 (6.9%)
pain	Multisite	129 (90.2%)	276 (94.5%)	405 (93.1%)
STarTBack:	Low	48 (33.8%)	109 (37.6%)	157
risk	Medium	67 (47.2%)	138 (47.6%)	(36.3%) 205(47.5%)
risk	High	27 (19.0%)	43 (14.8%)	70 (16.2%)
risk Classified as frail [◊] , n	. (%)	80 (55.9%)	130 (44.5%)	210
		. ,		(48.3%)
Self-rated outdoor w (IQR)	alking speed, median	4 (3, 4)	4 (3, 4)	4 (3, 4)
Change in mobility:	Better than one year	9 (6.3%)	15 (5.2%)	24 (5.5%)

Table 1 Baseline characteristics (Mean (standard deviation) or n (%) (unless stated)

ago			
About the same	30 (21.0%)	86 (29.5%)	116
			(26.7%)
Worse than one year ago	104 (72.7%)	191 (65.4.8%)	295
			(67.8%)
Use of walking aids outside:	40 (28.0%)	75 (25.7%)	115
Yes			(26.4%)
Sometimes	28 (19.6%)	55 (18.8%)	83 (19.1%)
Use of walking aids inside:	9 (6.3%)	16 (5.5%)	25 (5.7%)
Yes			
Sometimes	15 (10.5%)	35 (12.0%)	50 (11.5%)
Attitudes to Ageing Questionnaire [€]	28.7 (6.6)	29.0 (5.9)	28.9 (6.1)
Intention to exercise, median $(IQR)^{\text{F}}$	6 (6, 7)	6 (6, 7)	6 (6, 7)
Exercise self-efficacy scale [£] , median (IQR)	68 (54, 80)	70 (52, 81)	69 (53,
			80)
Walking self-efficacy [§]	5.3 (3.3)	5.7 (3.3)	5.6 (3.3)
Confidence in ability to self-manage	6.1 (1.78)	6.1 (1.81)	6.1 (1.80)
symptoms			
Fear Avoidance Beliefs $^{\circ}$	12.7 (5.4)	13.0 (6.1)	12.9 (5.9)

*IQR is Interquartile range; "baseline data for clinical outcomes is available in Table 2 and Table 3, Based on the Tilburg Frailty Index score of \geq 5; ^crange 8-40, higher score indicates a more positive attitude to ageing; [¥]range 1-7, higher scores indicates stronger intensions; [£]range 0-90, higher score indicates greater self-efficacy; [§]range 0-10 higher score indicates greater self-efficacy; [§]range 0-10 indicates

greater self-efficacy to walk 1/2 a mile; ¹⁷range 4-24, higher scores indicating greater fear avoidance

Receit

Outcome		Best Practice Advice		BOOST Programme		Between - Group	p-value
		n	Unadjusted mean (SD)*	n	Unadjusted mean (SD)*	Difference* (95% CI)	
ODI ^a	Baseline	143	32.3 (14.2)	292	33.2 (13.7)	n/a	
	6 months	125	33.2 (15.9)	258	30.2 (16.5)	-3.7 (-6.27, -1.06)	0.006
	12 months	127	33.0 (17.4)	253	31.7 (18)	-1.4 (-4.03, 1.17)	0.281
ODI Walking Item ^a	Baseline	143	1.8 (1.2)	292	1.8 (1.2)	n/a	
	6 months	125	1.8 (1.3)	258	1.6 (1.3)	-0.2 (-0.44, -0.02)	0.033
	12 months	126	1.9 (1.4)	253	1.6 (1.4)	-0.2 (-0.45, -0.01)	0.041
RADI - hours moving ^c ,	Baseline	143	3.0 (3.0, 4.0)	292	3.0 (2.0, 4.0)	n/a	
median (IQR)	6 months	125	3.0 (3.0, 4.0)	256	3.0 (2.0, 4.0)	$0.6 (0.39, 0.87)^{\text{F}}$	0.008
	12 months	127	3.0 (2.0, 4.0)	248	3.0 (2.0, 4.0)	$0.9 (0.61, 1.35)^{\text{¥}}$	0.633
RADI - hours sitting ^c ,	Baseline	143	3.0 (2.0, 3.0)	292	2.0 (2.0, 3.0)	n/a	
median (IQR)	6 months	125	3.0 (2.0, 3.0)	256	2.0 (2.0, 3.0)	$0.8 (0.49, 1.14)^{\text{F}}$	0.174
	12 months	127	2.0 (2.0, 3.0)	250	2.0 (2.0, 3.0)	$1.0(0.68, 1.55)^{\text{¥}}$	0.886
TFI ^b	Baseline	143	4.9 (2.50)	286	4.4 (2.70)	n/a	
	6 months	124	5.2 (2.70)	246	4.4 (2.80)	-0.4 (-0.80, 0.05)	0.085
C	12 months	124	5.2 (2.80)	241	4.8 (3.00)	0.1 (-0.34, 0.52)	0.676
TFI – physical subscale ^b	Baseline	143	3.0 (1.60)	290	2.6 (1.70)	n/a	
	6 months	125	3.1 (1.80)	250	2.6 (1.80)	-0.3 (-0.61, 0.00)	0.052
	12 months	125	3.1 (1.90)	245	2.8 (1.90)	0.0 (-0.33, 0.29)	0.918
TFI – psychological	Baseline	143	1.1 (1.00)	292	1.0 (1.10)	n/a	
subscale ^b	6 months	125	1.2 (1.10)	256	1.0 (1.00)	-0.1 (-0.31, 0.05)	0.152
	12 months	127	1.2 (1.00)	251	1.2 (1.10)	0.1 (-0.13, 0.24)	0.563
One of more falls ^e , n (%)	Baseline	143	50 (35%)	292	115 (39.4%)	n/a	
, , , ,	Over 12 months	125	59 (41.3%)	257	96 (32.9%)	$0.6~(0.40,0.98)^{ m {F}}$	0.041
Broken Bones following a	Baseline	143	4 (2.8%)	292	8 (2.7%)	n/a	
fall ^f , n (%)	Over 12 months	127	9 (7.1%)	253	17 (6.7%)	n/a	
SSS Symptom Scale ^b	Baseline	143	3.0 (0.60)	292	3.0 (0.60)	n/a	
	6 months	119	2.8 (0.80)	247	2.7 (0.80)	-0.2 (-0.28, -0.02)	0.025
	12 months	113	2.8 (0.80)	229	2.7 (0.80)	-0.1 (-0.19, 0.08)	0.428

-11

_	
Do	
nWi	
load	
aded	
from	
https	
sd	
laca	
~	
dem	
nic	
ò	
dno	
C	
/mo	
d/r	
/biom	
me	
b,	
Pro	
rontol	
8	
Q	
y/a	
0	
lvanc	
JC D	
nce-ar	
artic	
cle/c	
Ö.	
/doi/1	
10	
10.10	
10.10	
10.1093/g	
10.1093/ger	
10.1093/gerc	
10.1093/gerona/	
10.1093/gerona/gla	
10.1093/gerona/glac	
10.1093/gerona/glac06	
10.1093/gerona/glac063/6	
10.1093/gerona/glac063/6	
10.1093/gerona/glac063/6547	
10.1093/gerona/glac063/654788	
10.1093/gerona/glac063/6547887	
10.1093/gerona/glac063/6547887 by	
10.1093/gerona/glac063/6547887 by	
10.1093/gerona/glac063/6547887 by Kee	
10.1093/gerona/glac063/6547887 by Keele	
10.1093/gerona/glac063/6547887 by Keele Ur	
10.1093/gerona/glac063/6547887 by Keele Ur	
10.1093/gerona/glac063/6547887 by Keele Ur	
10.1093/gerona/glac063/6547887 by Keele Ui	
10.1093/gerona/glac063/6547887 by Keele University	
10.1093/gerona/glac063/6547887 by Keele University	
10.1093/gerona/glac063/6547887 by Keele University user	
10.1093/gerona/glac063/6547887 by Keele University	
10.1093/gerona/glac063/6547887 by Keele University user on 2	
10.1093/gerona/glac063/6547887 by Keele University user on 29	
10.1093/gerona/glac063/6547887 by Keele University user on 29 Ma	
10.1093/gerona/glac063/6547887 by Keele University user on 29	
10.1093/gerona/glac063/6547887 by Keele University user on 29 March	
10.1093/gerona/glac063/6547887 by Keele University user on 29 March 20	
10.1093/gerona/glac063/6547887 by Keele University user on 29 March	

			X			
		CC ¹				
Baseline	125	4.0 (3.0, 4.0)	258	4.0 (3.0, 4.0)	n/a	
6 months	125	3.0 (3.0, 4.0)	258	3.0 (2.0, 4.0)	$0.5 (0.27, 0.87)^{\text{F}}$	0.014
12 months	127	3.0 (2.0, 4.0)	253	3.0 (2.0, 4.0)	$0.8 (0.45, 1.43)^{\text{¥}}$	0.454
Baseline		n/a		n/a	n/a	
6 months	125	4.0 (3.0, 5.0)	257	3.0 (2.0, 5.0)	-0.4 (-0.75, -0.11)	0.009
12 months	127	4.0 (3.0, 5.0)	252	4.0 (3.0, 5.0)	0.0 (-0.30, 0.34)	0.902
Baseline		n/a		n/a	n/a	
6 months	125	3.0 (2.0, 4.0)	256	3.0 (2.0, 4.0)	$2.5(1.41, 4.44)^{\text{F}}$	0.002
12 months	126	2.0 (2.0, 4.0)	248	3.0 (2.0, 4.0)	$2.7 (1.54, 4.83)^{\text{F}}$	0.001
Baseline		n/a		n/a	n/a	
6 months	125	2.0 (2.0, 3.0)	256	3.0 (2.0, 4.0)	$3.1(1.63, 6.08)^{\text{F}}$	0.001
12 months	126	2.0 (2.0, 3.0)	247	2.0 (2.0, 3.0)	$1.8(0.91, 3.38)^{\text{F}}$	0.095
	6 months 12 months Baseline 6 months 12 months Baseline 6 months 12 months Baseline 6 months	6 months12512 months127Baseline1256 months12512 months127Baseline1256 months12512 months126Baseline1256 months125	6 months1253.0 (3.0, 4.0)12 months1273.0 (2.0, 4.0)Baselinen/a6 months1254.0 (3.0, 5.0)12 months1274.0 (3.0, 5.0)Baselinen/a6 months1253.0 (2.0, 4.0)12 months1262.0 (2.0, 4.0)Baselinen/a6 months1262.0 (2.0, 4.0)Baselinen/a6 months1252.0 (2.0, 3.0)	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		6 months125 $3.0(3.0, 4.0)$ 258 $3.0(2.0, 4.0)$ $0.5(0.27, 0.87)^{\$}$ 12 months127 $3.0(2.0, 4.0)$ 253 $3.0(2.0, 4.0)$ $0.8(0.45, 1.43)^{\$}$ Baselinen/an/an/a6 months125 $4.0(3.0, 5.0)$ 257 $3.0(2.0, 5.0)$ $-0.4(-0.75, -0.11)$ 12 months127 $4.0(3.0, 5.0)$ 252 $4.0(3.0, 5.0)$ $0.0(-0.30, 0.34)$ Baselinen/an/an/a6 months125 $3.0(2.0, 4.0)$ 256 $3.0(2.0, 4.0)$ $2.5(1.41, 4.44)^{\$}$ 12 months126 $2.0(2.0, 4.0)$ 248 $3.0(2.0, 4.0)$ $2.7(1.54, 4.83)^{\$}$ Baselinen/an/an/a $1/a$ 6 months125 $2.0(2.0, 3.0)$ 256 $3.0(2.0, 4.0)$ $3.1(1.63, 6.08)^{\$}$

Notes: *Unless indicated ^{*}Adjusted Odds Ratio (95% CI). ^aODI analysis adjusted for age, gender & baseline ODI. Model includes repeated measures with random effects for participant and centre. 403 participants contributed to the model. ^b Mixed effects linear regression analysis adjusted for age, gender and baseline score, with repeated measures within participant and centre, and time point-by-treatment interaction. ^cMixed effects linear regression analysis adjusted for age, gender and baseline score, with repeated measures within participant and centre, and time point-by-treatment interaction. ^d Mixed effects linear regression analysis adjusted for age and gender with repeated measures within participant and centre, and time point-by-treatment interaction. ^eMixed effects linear and baseline score, with repeated measures within participant and centre, and time point-by-treatment interaction. ^eMixed effects logistic regression analysis adjusted for age and gender with repeated measures within participant and centre, and time point-by-treatment interaction. ^eMixed effects logistic regression analysis adjusted for age and gender with repeated measures within participant and centre, and time point-by-treatment interaction. ^eMixed effects logistic regression analysis adjusted for age and gender with repeated measures within participant and centre, and time point-by-treatment interaction. ^fGiven the low event rate reported for number of broken bones following fall, no statistical test was used for comparison. ^g Participant satisfaction mixed effects ordinal logistic regression analysis adjusted for age and gender with repeated observations within participant and centre; breakdown of scores from 0 to 4 are presented in Supplementary Information Table S3. IQR- Interquartile Range; CI-Confidence Interval; SD- Standard Deviation; ODI-Oswestry Disability Index; RADI-Rapid Assessment Disuse Index; TFI-Tilburg Frailty Index


Table 3 Outcomes – physical tests

Table 3 Outcomes – physical tests									
Outcome		n	Best Practice Advice Unadjusted mean	n	BOOST Programme Unadjusted mea	Between - Group an Difference	p-value		
Outcome		11	Unadjusted mean (SD)*	11	Unadjusted mea (SD)*	(95% CI)			
6 minute walk	Baseline	143	260.4 (101.30)	292	252.9 (98.10)	n/a			
test ^a	6 months	118	266.3 (103.40)	240	283.5 (99.40)	22.5 (7.11, 37.82)	0.004		
	12 months	111	263.2 (106.70)	216	284.7 (105.40)	21.7 (5.96, 37.38)	0.007		
SPPB ^a ,	Baseline	143	9.0 (8.00, 11.00)	291	9.0 (7.00, 11.00)	n/a			
median (IQR)	6 months	118	9.0 (7.00, 11.00)	245	10.0 (8.00, 11.00)	0.6 (0.19, 0.97)	0.003		
	12 months	112	9.5 (7.00, 11.00)	218	10.5 (8.00, 12.00)	0.4 (0.00, 0.80)	0.052		
Grip	Baseline	143	26.7 (10.50)	292	26.7 (10.50)				
Strength ^a	6 months	118	26.1 (11.10)	247	27.1 (10.60)	1.2 (0.28, 2.11)	0.010		
	12 months	112	26.4 (11.30)	225	27.0 (10.60)	0.9 (-0.08, 1.79)	0.073		

Notes: *Unless indicated. *Mixed effects linear regression analysis adjusted for age, gender and baseline score, with repeated measures within participant and centre, and time point-by-treatment interaction. IQR-Interquartile Range; CI-Confidence Interval; SD- Standard Deviation; SPPB-Short Physical Performance Battery







* Numbers included in analysis is all participants with at least one follow-up ODI outcome and the baseline variables used in the model.

Reek

